drugset / Trial / NCT07824505
Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Indication: Patients with advanced recurrent or metastatic thymic carcinoma. Phase IIa (China only):Approximately 6 patients. Phase IIb (China only):Approximately 54 patients.
Timeline
- Start
- 2018-08-16
- Primary completion
- 2021-09-06
- Completion
- 2021-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lucitanib | Small molecule | 10 mg | Oral |
| Subject | Lucitanib | Small molecule | 15 mg | Oral |